Ovid Therapeutics Q4 2023 GAAP EPS $(0.220) Misses $(0.100) Estimate, Sales $141.562K Beat $56.500K Estimate
Portfolio Pulse from Benzinga Newsdesk
Ovid Therapeutics reported Q4 2023 GAAP EPS of $(0.220), missing the $(0.100) estimate, but its sales of $141.562K exceeded the $56.500K estimate, marking a 205.88% increase from the previous year.
March 08, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ovid Therapeutics missed EPS estimates but significantly beat sales forecasts for Q4 2023, with a notable year-over-year sales increase.
While the EPS miss is negative, the substantial beat on sales forecasts and the significant year-over-year sales growth could offset investor concerns, leading to a neutral short-term impact on OVID's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100